Gerald L. Andriole, Jr., MD

Gerald L. Andriole, Jr., MD

Barnes-Jewish Hospital and Washington University School of Medicine

St. Louis, Missouri

Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, MO. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, PA. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residencies at Brigham and Women’s Hospital and Harvard Medical School. He was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, MD. He has contributed over 400 peer-reviewed publications and serves on the editorial boards of several journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain and Symptoms of Lower Urinary Tract Dysfunction Research Network. He was also Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial. He is a member of the American Urological Association, American Association for Cancer Research, and the American Society of Clinical Oncology, among other societies.

Articles by Gerald L. Andriole, Jr., MD

Biomarkers for Prostate Cancer: Whom to Treat

Gerald L. Andriole, Jr., MD, discusses the limitations and successes in the design of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSPC) trials. He also emphasizes the importance of patient selection in PSA screening and utilizing other diagnostic methods.

Read More

Prostate Cancer Screening: Who? Why? How?

Gerald L. Andriole, Jr., MD, discusses the limitations and successes in the design of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSPC) trials. He also emphasizes the importance of patient selection in PSA screening and utilizing other diagnostic methods.

Read More

Join the GRU Community

- Why Join? -